Acecardol, tablets 100 mg, 50 pcs.

The mechanism of action of acetylsalicylic acid (ASA) is based on irreversible inhibition of cyclooxygenase, which results in blocking the synthesis of thromboxane A2 and inhibiting platelet aggregation.

Asc is believed to have other mechanisms to inhibit platelet aggregation, which expands its application in various vascular diseases. ASK also has anti-inflammatory, analgesic, and antipyretic effects.

Indications

Prevention of acute myocardial infarction in the presence of risk factors (e.g., diabetes, hyperlipidemia, hypertension, obesity, smoking, old age) and recurrent myocardial infarction.

Unstable angina pectoris.

Prevention of stroke (including in patients with transient cerebral circulation disorder).

The prevention of thromboembolism after operations and invasive vascular interventions (e.g., coronary artery bypass surgery, carotid endarterectomy, arterio-venous bypass, carotid angioplasty).

Prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches (e.g., in case of prolonged immobilization due to major surgical intervention)

Active ingredient

Composition

Composition of the drug:

1 tablet of ACECARDOL contains 50, 100 or 300 mg of acetylsalicylic acid (active ingredient).

Auxiliary substances:

povidone,

corn starch,

Milk sugar (lactose),

Microcrystalline cellulose,

magnesium stearate (magnesium stearate),

talc,

p> acetylphthalyl cellulose,

titanium dioxide,

castor oil.

How to take, the dosage

The tablets should be taken orally before meals with plenty of fluids. The drug is intended for long-term use. The duration of therapy is determined by the attending physician.

Prophylaxis in case of suspected acute myocardial infarction: 100 to 200 mg/day or 300 mg every other day (the first tablet should be chewed for rapid absorption).

Prevention of first-time acute myocardial infarction in the presence of risk factors: 100 mg/day or 300 mg every other day.

Prevention of recurrent myocardial infarction. Unstable angina pectoris. Prevention of stroke and transient impairment of cerebral circulation. Prevention of thromboembolic complications after surgery or invasive investigations: 100 to 300 mg/day.

Prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches: 100 – 200 mg/day or 300 mg every other day.

Interaction

When used concomitantly ASA increases the effect of the following drugs:

Special Instructions

The drug should be used after prescribing by a physician. ASA may provoke bronchospasm, as well as cause attacks of bronchial asthma and other hypersensitivity reactions. Risk factors include a history of bronchial asthma, hay fever, nasal polyposis, chronic respiratory diseases, and allergic reactions to other drugs (e.g., skin reactions, itching, urticaria). ASA may cause bleeding of varying severity during and after surgical interventions. Combination of ASA with anticoagulants, thrombolytics and antiplatelet agents is accompanied by an increased risk of bleeding. Low doses of ASA can provoke development of gout in predisposed persons (those with decreased excretion of uric acid). The combination of ASA and methotrexate is accompanied by an increased incidence of side effects from the hemopoietic organs.

High doses of ASA have a hypoglycemic effect, which should be considered when prescribing it for patients with diabetes mellitus who are treated with hypoglycemic agents. When concomitant administration of GCS and salicylates, it should be remembered that during treatment, blood levels of salicylates are decreased, and an overdose of salicylates is possible after withdrawal of GCS.

The combination of ASA with ibuprofen is not recommended because the latter worsens the beneficial effects of Acecardol on longevity. Increasing the dose of ASA is associated with the risk of gastrointestinal bleeding. Overdose is especially dangerous in elderly patients. When ASA is combined with alcohol, there is an increased risk of gastrointestinal mucosal damage and prolonged bleeding time.

Impact on the ability to drive/mechanisms: Not observed.

Contraindications

Hypersensitivity to ASA, excipients of the drug and other NSAIDs.

. Ulcerative lesions, gastrointestinal bleeding, hemorrhagic diathesis, bronchial asthma induced by taking salicylates and NSAIDs, Fernand-Vidal triad, (combination of bronchial asthma, (combined bronchial asthma, recurrent nasal and paranasal sinus polyposis, and ASA intolerance), concomitant use with methotrexate at a dose of 15 mg per week or more pregnancy (I and III trimesters) and lactation Age

Side effects

Allergic reactions: urticaria, Quincke’s edema.

Immune system: anaphylactic reactions.

Gastrointestinal tract: nausea, heartburn, vomiting, abdominal pain, mucous membrane ulcers of the stomach and duodenum, including perforative, gastrointestinal bleeding, increased activity of “liver” enzymes.

Respiratory system: bronchospasm

Hematopoietic system: increased bleeding, anemia (rare).

Central nervous system: dizziness, tinnitus

Overdose

Symptoms of moderate overdose: nausea, vomiting, tinnitus, hearing impairment, dizziness, confusion.

Treatment: reduction of the drug dose.

Severe overdose symptoms: Fever, hyperventilation, ketoacidosis, respiratory alkalosis, coma, cardiovascular and respiratory failure, severe hypoglycemia.

Treatment: immediate hospitalization in specialized departments for emergency therapy gastric lavage, determination of acid-base balance, alkaline and forced alkaline diuresis, hemodialysis, administration of solutions, activated carbon, symptomatic therapy. When performing alkaline diuresis, it is necessary to achieve pH values between 7.5 and 8. Forced alkaline diuresis should be performed when plasma concentration of salicylates is over 500 mg/l (3.6 mmol/l) in adults and 300 mg/l (2.2 mmol/l) in children.

Similarities